OCGN Ocugen, Inc.
Legal ·
The 10-Q says the defendants in the Pennsylvania class action are the company and "certain of its agents" and names none. Derivative suits in two courts are stayed, and a Delaware class action over the charter was dismissed as moot.
The notes include the full exercise of a $15.0 million over-allotment option. Ocugen used approximately $32.7 million of the proceeds to repay its Avenue loan.
Ocugen plans $115 million of 6.75% convertible senior notes due 2034, with an option that takes the total to $130 million. Proceeds include $32.7 million to retire Avenue debt at 12.5%.
The registered direct offering covers 20,000,000 shares and warrants for 20,000,000 more at $1.50. Full warrant exercise could bring up to $30 million more.
Ocugen's stock closed at or above $1.00 for ten business days from July 8, 2025 to July 25, 2025. Nasdaq said on July 28, 2025, that the matter is closed.
Nasdaq granted Ocugen (Nasdaq: OCGN) an additional 180 calendar days to regain compliance with the $1.00 minimum closing bid price requirement. The first period ended June 30, 2025.
OrthoCellix's stockholder and the concurrent financing investors are expected to own about 90% of the combined company, with Carisma holders at about 10%. The deal is all stock and needs approval from both companies' stockholders.
Ocugen received a Nasdaq deficiency notice because its stock closed below $1.00 for 30 consecutive business days. It has until June 30, 2025 to regain compliance and may qualify for a second 180-day period.
Ocugen is aiming to redefine the future of vision through gene therapies. Its platform is a modifier gene therapy approach based on nuclear hormone receptors, which the company says has the potential to address blindness diseases with a gene-agnostic approach. Its lead program, OCU400, is intended for retinitis pigmentosa (RP), has completed enrollment in the Phase 3 liMeliGhT trial, and is on track for a rolling BLA submission in the third quarter of 2026, with topline Phase 3 data expected in the first quarter of 2027. OCU410ST targets Stargardt disease in the Phase 2/3 GARDian3 pivotal confirmatory trial, where dosing began in July 2025, and a BLA is planned for the first half of 2027. OCU410 is being developed for geographic atrophy secondary to dry age-related macular degeneration, and dosing in Phase 2 of the Phase 1/2 ArMaDa trial has been completed. The company says its programs use the RORA gene delivered by subretinal AAV5.
| Product or program | What it is | Stage |
|---|---|---|
| OCU400 | Modifier gene therapy for retinitis pigmentosa | Phase 3 |
| OCU410ST | Modifier gene therapy for Stargardt disease (ABCA4-associated retinopathies) | Phase 2/3 |
| OCU410 | Modifier gene therapy for geographic atrophy secondary to dry AMD | Phase 1/2, dosing completed |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $39.8 million | $32.1 million |
| Net income (loss) | -$67.8 million | -$54.1 million |
| Cash from operations | -$57.0 million | -$42.1 million |
| Cash and equivalents | $18.6 million | $58.8 million |
Our latest story on this, dated Aug 6, 2026: "Ocugen awaits Third Circuit ruling in dismissed securities suit as derivative suits remain stayed". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 5, 2026: "Ocugen plans $115 million convertible senior notes offering". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 14, 2026: "Ocugen closes $130.0 million of 6.75% convertible notes". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 3, 2025: "Ocugen gets Nasdaq minimum bid price deficiency notice, has until June 30, 2025". The story links the filing or release it is based on. Read the story.
Ocugen, Inc. trades under the ticker OCGN on NASDAQ.
Ocugen, Inc. is listed on NASDAQ. Our directory also records these other listings: BIVA:OCGN; BMV:OCGN; DUS:2H51; FWB:2H51; GETTEX:2H51; HAM:2H51; HAN:2H51; LS:A2PSZH; LSX:A2PSZH; MUN:2H51; SWB:2H51; TRADEGATE:2H51; XETR:2H51.
The SEC Central Index Key (CIK) for Ocugen, Inc. is 1372299. Its filings are on SEC EDGAR.
339,110,401 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Ocugen, Inc. under United States.
Our directory classifies Ocugen, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Ocugen, Inc. is US67577C1053.
aibio.space lists Ocugen, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Ocugen is aiming to redefine the future of vision through gene therapies. Its platform is a modifier gene therapy approach based on nuclear hormone receptors, which the company says has the potential to address blindness diseases with a gene-agnostic approach.
OCU400: Modifier gene therapy for retinitis pigmentosa Stage: Phase 3.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 8.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio